Correlation of Epidermal Growth Factor Receptor (EGFR) Mutation Status with Patient Demographics and Specimen Characteristics in Non-small Cell Lung Carcinoma (NSCLC)
Article Sidebar
Main Article Content
Abstract
Background: Lung cancer is the leading cause of cancer-related mortality. Targeted therapy of EGFR-TKIs in advanced NSCLC patients with EGFR mutation has potentially increased survival rate. NSCLC has historically been associated with young, non-smoking, female patients.
Objective: To evaluate the correlation of EGFR mutation status with patient demographics and specimen characteristics in NSCLC.
Methods: The study was a retrospective observational case-control study. The medical records and pathological reports of Thai patients who lived in Surin province and were diagnosed of NSCLC at Surin hospital from January 1st, 2017 to December 31st, 2021 were reviewed. Descriptive data were expressed in mean, standard deviation, min-max, and percentage. The relationships of factors affecting the EGFR status were analyzed using logistic regression analysis.
Results: All 189 patients were evaluated. 55.5% of all the specimens showed EGRF mutations, mainly was exon 19 (58.1%). Mostly were surgical specimens (90.4%) from biopsy procedure (84.1%) which mainly from lung or bronchus (53.4%). Adenocarcinoma was predominantly diagnosed (70.0%). The mutations showed statistically significant between female [OR=2.75, 95% CI (1.51-5.02), p=0.001], non-smoking [OR=2.39, 95% CI (1.27-4.52), p=0.016], lung or bronchial specimen [OR=4.35, 95% CI (1.78-10.64), p=0.003], adenocarcinoma [OR=6.97, 95% CI (2.14-22.73), p<0.001], and TTF-1 expression [OR=4.08, 95% CI (1.19-13.92), p=0.018].
Conclusion: The EGFR mutations occurred significantly in female, non-smoking patient, lung or bronchial specimen, diagnosed of adenocarcinoma, and TTF-1 positive.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65(2):87-108. doi: 10.3322/caac.21262.
สุพัตรา รักเอียด, ศุกล ภักดีนิติ, วิษณุ ปานจันทร์, อาคม ชัยวีระวัฒนะ, วีรวุฒิ อิ่มสำราญ, บรรณาธิการ. แนวทางการตรวจวินิจฉัยและรักษาโรคมะเร็งปอด (ปรับปรุงครั้งที่ 2). กรุงเทพฯ : โฆษิตการพิมพ์ ; 2558.
Borczuk AC, Chan JKC, Cooper WA, Dacic S, Kerr KM, Lantuejoul S, et al. Tumours of the lung. In : The WHO Classification of Tumours Editorial Board. WHO Classification of Thoracic Tumors. 5th ed. Lyon : International Agency for Research on Cancer ; 2021:19-36.
Chang JT, Jeon J, Sriplung H, Yeesoonsang S, Bilheem S, Rozek L, et al. Temporal Trends and Geographic Patterns of Lung Cancer Incidence by Histology in Thailand, 1990 to 2014. J Glob Oncol 2018;4:1-29. doi: 10.1200/JGO.18.00013.
Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 2012;25(3):347-69. doi: 10.1038/modpathol.2011.215.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361(10):947-57. doi: 10.1056/NEJMoa0810699.
Musayeva M, Sak SD, Özakıncı H, Boyacıgil Ş, Coşkun Ö. Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: A study of 600 cases from a single center. Turk Gogus Kalp Damar Cerrahisi Derg 2020;28(1):143-50. doi: 10.5606/tgkdc.dergisi.2020.18196.
Graham RP, Treece AL, Lindeman NI, Vasalos P, Shan M, Jennings LJ, et al. Worldwide Frequency of Commonly Detected EGFR Mutations. Arch Pathol Lab Med 2018;142(2):163-7. doi: 10.5858/arpa.2016-0579-CP.
Calibasi-Kocal G, Amirfallah A, Sever T, Umit Unal O, Gurel D, Oztop I, et al. EGFR mutation status in a series of Turkish non-small cell lung cancer patients. Biomed Rep 2020;13(2):2. doi: 10.3892/br.2020.1308.
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013;8(7):823-59. doi: 10.1097/JTO.0b013e318290868f.
Tomonaga N, Nakamura Y, Yamaguchi H, Ikeda T, Mizoguchi K, Motoshima K, et al. Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer 2013;14(5):521-6. doi: 10.1016/j.cllc.2013.04.005.
Villa C, Cagle PT, Johnson M, Patel JD, Yeldandi AV, Raj R, et al. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med 2014;138(10):1353-7. doi: 10.5858/arpa.2013-0376-OA.
Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, et al. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification]. [Article in Chinese]. Zhonghua Bing Li Xue Za Zhi 2012;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001.
Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol 2012;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515.
da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011;119(2):80-91. doi: 10.1002/cncy.20150.
Ma ES, Ng WK, Wong CL. EGFR gene mutation study in cytology specimens. Acta Cytol 2012;56(6):661-8. doi: 10.1159/000343606.
Shanzhi W, Yiping H, Ling H, Jianming Z, Qiang L. The relationship between TTF-1 expression and EGFR mutations in lung adenocarcinomas. PLoS One 2014;9(4):e95479. doi: 10.1371/journal.pone.0095479.
Li W, Niehaus AG, O'Neill SS. Immunohistochemistry Profile Predicts EGFR Mutation Status in Lung Adenocarcinoma. Int J Surg Pathol 2020;28(5):502-6. doi: 10.1177/1066896920909427.
Chen C, Shen D, Li J, Sun Y, Wang J. TTF-1 and EGFR expression are related to EGFR mutation in lung adenocarcinoma. Int J Clin Exp Pathol 2018;11(9):4650-6. PMID: 31949865
